PT  - JOURNAL ARTICLE
AU  - Pellegrini, Marco
TI  - Accurate prognosis for localized prostate cancer through coherent voting networks with multi-omic and clinical data
AID  - 10.1101/2022.07.28.22278156
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.07.28.22278156
4099  - http://medrxiv.org/content/early/2023/01/09/2022.07.28.22278156.short
4100  - http://medrxiv.org/content/early/2023/01/09/2022.07.28.22278156.full
AB  - Background Prostate cancer is a very heterogeneous disease, from both a clinical and a biological/biochemical point of view, which makes the task of producing a stratification of patients into risk classes remarkably challenging. In particular, it is important an early detection and discrimination of the more indolent forms of the disease, from the more aggressive ones, requiring closer surveillance and timely treatment decisions.Methods We extend a recently developed supervised machine learning (ML) technique, called coherent voting networks (CVN) by incorporating novel model-selection technique to counter model overfitting. The CVN method is then applied to the problem of predicting an accurate prognosis (with a time granularity of 1 year) for patients affected by prostate cancer. The CVN is developed on a discovery cohort of 495 patients from the TCGA-PRAD collection, and validated on several other independent cohorts, comprising a gross total of 744 patients.Findings We uncover seven multi-gene fingerprints, each comprising six to seven genes, and a mixed clinical and genomic 5-marker fingerprint, that correspond to different input data types (clinical, mRNA expression, proteomic assays, methylation) and different time points, for the event of post-surgery progression-free survival (PFS) in patients diagnosed with prostate adenocarcinoma, who had not received prior treatment for their disease.With a mixed 5-marker genomic and clinical fingerprint comprising Gleason primary score, tumor stage, psa, and molecular protein expression levels for CDKN1B and NF2 we attain on three independent cohorts statistically significant AUC values of 0.85, 0.88, and 0.87 respectively for PFS prediction at 3 years.For purely genomic fingerprints, in seven independent cohorts for 21 combinations of cohort vs fingerprint, we report Odds Ratios ranging from a minimum of 9.0 and a maximum of 40.0, with average 17.5, geometric mean p-value 0.003; Cohen’s kappa values ranging from a minimum of 0.18 to a maximum of 0.65, with average 0.4; and AUC ranging from a minimum of 0.61 to a maximum of 0.88, with average 0.76, geometric mean p-value 0.001, for PFS prediction at 2, 3, and 4 years.Many of the genes in our fingerprint have recorded prognostic power in some form of cancer, and have been studied for their functional roles in cancer on animal models or cell lines.Interpretation The development of novel ML techniques tailored to the problem of uncovering effective multi-gene prognostic biomarkers is a promising new line of attack for sharpening our capability to diversify and personalize cancer patient treatments. For the challenging problem of discriminating a fine time-scale for aggressive types of localized prostate cancer, we show that it is possible to attain more accurate prognostic predictions, with a granularity within a year, for the post-surgery early years.Competing Interest StatementDr. Pellegrini has a patent application EP 20202942.7 pending to the National Research Council of Italy, a patent application IT 102019000019571 pending to the National Research Council of Italy, a patent application IT 102019000019556 pending to the National Research Council of Italy, and a US patent application #17077294 pending to the National Research Council of Italy.Funding StatementThe research exposed in this article has been conducted as curiosity-driven free research by the author.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.cbioportal.org https://xena.ucsc.edu https://www.ncbi.nlm.nih.gov/geo/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability Data supporting the findings of this study are available from the Github repository https://github.com/MarcoPellegriniCNR/Coherent-Voting-Network-for-PRC-prognosis. Code availability Custom software and code availability is to be agreed via licensing contracts with the National Research Council of Italy. https://github.com/MarcoPellegriniCNR/Coherent-Voting-Network-for-PRC-prognosis